CLNN · Clene Inc. · Executive Compensation
$3.75
+0.02 (+0.54%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern. To mitigate our funding needs, we plan to raise additional funding, including exploring equity financing and offerings, debt financing, licensing or collaboration arrangements with third parties, as well as utilizing our existing at-the-market facility and potential proceeds from the exercise of outstanding warrants and stock options. These plans are subject to market conditions and reliance on third parties, and there is no assurance that effective implementation of our plans will result in the necessary funding to continue current operations. During the three and six months ended June 30, 2026, we raised $7.0 million and $13.0 million, respectively, of gross proceeds from registered direct offerings of equity securities (see Note 13 to the condensed consolidated financial statements). While we have implemented cost-saving initiatives, including delaying and reducing certain research and development programs and commercialization efforts, reducing employee compensation, and eliminating certain staff positions, we have concluded that our plans do not alleviate the substantial doubt about our ability to continue as a going concern beyond one year from the date the condensed consolidated financial statements contained in this report are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$47.92M
Shares
12.85M
Volume · Oct 20
202.01K
Avg daily vol (3M)
106.18K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Robert Etherington | President and Chief Executive Officer | $933,394 |
| Mark Mortenson | Chief Science Officer | $809,426 |
| Morgan R. Brown | Chief Financial Officer | $487,650 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Robert Etherington | President and Chief Executive Officer | $1,367,727 |
| Mark Mortenson | Chief Science Officer | $1,078,619 |
| Morgan R. Brown | Chief Financial Officer | $760,567 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Robert Etherington | President and Chief Executive Officer | $1,706,605 |
| Mark Mortenson | Chief Science Officer | $1,377,982 |
| Morgan R. Brown | Chief Financial Officer | $993,698 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Robert Etherington | President and Chief Executive Officer | $2,181,629 |
| Mark Mortenson | Chief Science Officer | $1,285,504 |
| Morgan R. Brown | Chief Financial Officer | $1,158,780 |
| Dr. Robert Glanzman | Chief Medical Officer | $735,510 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Robert Etherington | President and Chief Executive Officer | $5,101,808 |
| Mark Mortenson | Chief Science Officer | $2,641,804 |
| Dr. Robert Glanzman | Chief Medical Officer | $1,546,858 |
| Robert Glanzman | Chief Medical Officer | $1,546,857 |
| Morgan R. Brown | Chief Financial Officer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Robert Etherington | Chief Executive Officer | $497,631 |
| Mark Mortenson | Chief Science Officer | $466,131 |
| Robert Glanzman | Chief Medical Officer | $447,203 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Robert Etherington | — | $504,020 |
| Mark Mortenson | — | $442,520 |
| Robert Glanzman | — | $370,677 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Robert Etherington | — | $464,504 |
| Mark Mortenson | — | $415,254 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Shalom Jacobovitz | Class III director | Appointed | 2026-05-22 |
| Alison H. Mosca | Class III director | Appointed | 2026-05-22 |
| Robert Etherington | Class III director | Appointed | 2026-05-22 |
| Arjun “JJ” Desai, M.D. | Class II directors | Appointed | 2025-05-23 |
| Matthew Kiernan AM, Ph.D., DSc | Class II directors | Appointed | 2025-05-23 |
| David J. Matlin | Class II directors | Appointed | 2025-05-23 |
| Reed N. Wilcox | Class I director | Appointed | 2024-05-30 |
| Vallerie V. McLaughlin, M.D. | Class I director | Appointed | 2024-05-30 |
| Jonathon T. Gay | Class I director | Appointed | 2024-05-30 |
| John H. Stevens | Class II director | Retired | 2023-09-19 |
| Arjun (JJ) Desai | Class II Director | Appointed | 2023-09-19 |
| Matthew Kiernan | Class II Director | Appointed | 2023-09-19 |
| Shalom Jacobovitz | Class III director | Appointed | 2023-05-11 |
| Alison H. Mosca | Class III director | Appointed | 2023-05-11 |
| Robert Etherington | Class III director | Appointed | 2023-05-11 |
| Benjamin Greenberg, M.D., M.H.S. | Head of Medical | Appointed | 2023-03-17 |
| Robert Glanzman, M.D., FAAN | Chief Medical Officer | Retired | 2023-03-17 |
| Chidozie Ugwumba | Class II director | Resigned | 2023-02-17 |
Leadership
- Robert Etherington CEO, Board Member
- Morgan Brown CFO
- Morgan R. Brown CFO
- Alison H. Mosca Board Member
- Arjun "JJ" Desai, M.D. Board Member
- Arjun (JJ) Desai Board Member
- Arjun “JJ” Desai, M.D. Board Member
- Jonathon T. Gay Board Member
- Matthew Kiernan Board Member
- Matthew Kiernan AM, Ph.D., DSc Board Member
- Shalom Jacobovitz Board Member
- Vallerie V. McLaughlin, M.D. Board Member